A Study of [14C]-LY4065967 in Healthy Participants (NCT07039045) | Clinical Trial Compass
CompletedPhase 1
A Study of [14C]-LY4065967 in Healthy Participants
United States16 participantsStarted 2025-06-23
Plain-language summary
The purpose of this study is to investigate the absorption, metabolism, excretion, and bioavailability of LY4065967 in healthy male participants. This is a 2-part study. The study will last about 58 days for participants in Part 1 and about 60 days for participants in Part 2.
Who can participate
Age range18 Years – 55 Years
SexMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and 12-lead electrocardiograms (ECGs).
* Have clinical laboratory test results within normal reference range for the population or investigative site, or results with acceptable deviations that are judged to be not clinically significant by the investigator.
* Have venous access sufficient to allow for blood sampling.
* Currently have a minimum of 1 bowel movement per day.
* Have a body mass index within 18.0 to 35.0 kg/m², inclusive
* Assigned male at birth
Exclusion Criteria
* Have significant previous or current history of cardiovascular, respiratory, hepatic, renal, GI, endocrine, hematological, neurological, thromboembolism, or bleeding disorder capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study intervention; or of interfering with the interpretation of data.
* Have a significant history of or current psychiatric disorders.
* Have history of stomach or intestinal surgery or resection that would potentially alter absorption or excretion of orally administered drugs. Uncomplicated appendectomy, uncomplicated cholecystectomy, and hernia repair will be allowed.
* Have a history of significant chronic constipation or have had acute constipation within 3 weeks prior to check-in.
* Have any abnormality in the 12-lead ECG at screening that, in the opinio…
What they're measuring
1
Part 1: Percentage of Total Radioactive Dose in Urine and Fecal Excretion
Timeframe: Baseline through Study Completion (21 days)
2
Part 2: Plasma Area Under the Concentration-time Curve from Zero to Infinity (AUC(0-ꝏ)) for LY4065967
Timeframe: Baseline through Study Completion (9 Days)